Cellectar Biosciences, Inc. Series A Warrants (CLRBZ)

0.06
0.00 (0.00)
NASDAQ
Prev Close 0.06
Open 0.06
Day Low/High 0.06 / 0.06
52 Wk Low/High 0.02 / 0.26
Volume 2.00K
Exchange NASDAQ
Div & Yield N.A. (N.A)

Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

Covers composition of matter and method of use for proprietary PDCs™ in combination with anti-cancer agents

Cellectar Reports 2017 Financial Results And Provides A Corporate Update

Conference call to be held tomorrow at 8:30 a.m. Eastern time

Cellectar Announces Expansion Of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial Of CLR 131

Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit

Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

Covers composition of matter and method of use for proprietary PDCs™ in combination with anti-cancer agents

Cellectar Reports 2017 Financial Results And Provides A Corporate Update

Cellectar Reports 2017 Financial Results And Provides A Corporate Update

Conference call to be held tomorrow at 8:30 a.m. Eastern time

Cellectar Announces Expansion Of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial Of CLR 131

Cellectar Announces Expansion Of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial Of CLR 131

Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit